Razagilin

Azagilin tablets are indicated for idiopathic parkinsonism or as adjuvant therapy (using levodopa) with fluctuations in the final dose.

Structure

Active ingredient: razagilin.

1 tablet contains - 1.44 mg of rasagiline tartrate, which corresponds to - 1 mg of rasagiline.

Excipients: trehalose dihydrate, corn starch, colloidal silicon dioxide, citric acid, talc, stearic acid, microcrystalline cellulose, croscarmellose sodium.

Contraindications

Hypersensitivity to the active substance or to any other component of the drug.

Severe liver failure.

Mode of application

Assign orally in a dose of 1 mg 1 time per day with or without levodopa.

The drug can be used regardless of food intake.

Application features

Pregnant women

Not recommended.

Children

Not recommended.

Drivers

May affect the ability to drive vehicles or operate machinery.

Overdose

• Hypomania.
• Hypertensive crisis.
• Serotonin syndrome.
• Dysphoria.

Side effects

• Carcinoma of the skin.
• Leukopenia
• Allergy.
• Depression.
• Hallucinations.
• Headache.

Interaction

Razagilin should not be used simultaneously with other MAO inhibitors (including drugs and herbal preparations containing St. Johns wort perforated), since there is a risk of non-selective inhibition, which can lead to the development of a hypertensive crisis.

Storage conditions

Keep out of reach of children in the original packaging at a temperature not exceeding 30 ° C.

Shelf life is 4 years.